Global Epigenetics Drugs and Diagnostic Technologies Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 794898
  • |
  • Publishe Date : February 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Epigenetics Drugs and Diagnostic Technologies Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Rising incidence of cancer is the main factor driving the growth of the market.

A rise in the number of aged people worldwide, Large investments in R&D activities and advancement in screening techniques are the factors driving the growth of the epigenetics drugs and diagnostic technologies market.
Factors, such as Scarcity of trained professionals will restrain the market growth in the forecast period.
Growing potentials in emerging markets Market in the forecast period will create an positive impact on the market.

Based on type of epigenetic therapies, the market is segmented into Histone Deacetylase (HDAC) inhibitors and DNA Methyltransferase (DNMT) inhibitors. The DNMT inhibitors was the largest revenue generating segment in 2017 owing to the factors such as wide scale availability in most regions.

Based on application the Epigenetics Drugs and Diagnostic Technologies market is segmented into, oncology and non oncology.
Regionally North America is the dominant region segment of this market. Presence of government funding programs for ongoing research activities, better healthcare facilities, and constantly growing geriatric population are some of the prominent driving factors.
Some of the key players operating in this market include Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; Novartis AG; Illumina, Inc.; Merck Sharp & Dohme Corp; Qiagen; Abcam PLC; and Merck KGaA
Key Benefits of the Report:
* Global, Regional, Country, Type, and Route of Application Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Type& Application, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Epigenetics Drugs and Diagnostic Technologies providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies


Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity Application, spending were taken into consideration.
We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.
The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Type Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute
* Pharmacies

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET — INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Epigenetics Drugs and Diagnostic Technologies Market — Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Epigenetics Drugs and Diagnostic Technologies Market — Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Epigenetics Drugs and Diagnostic Technologies Market Company Market Share, 2017
3.6 Epigenetics Drugs and Diagnostic Technologies Market — Porter\'s Five Forces Analysis
3.7 Epigenetics Drugs and Diagnostic Technologies Market — Pestel Analysis

4 EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET TYPE OUTLOOK
4.1 Epigenetics Drugs and Diagnostic Technologies Market Share by Type, 2016 & 2025
4.2 Histone Deacetylase (HDAC) inhibitors
4.3 DNA Methyltransferase (DNMT) inhibitors


5 EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET APPLICATION OUTLOOK
5.1 Epigenetics Drugs and Diagnostic Technologies Market Share by Application, 2016 & 2025
5.2 Oncology
5.3 Non Oncology

6 EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET REGIONAL OUTLOOK
6.1 Epigenetics Drugs and Diagnostic Technologies Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Epigenetics Drugs and Diagnostic Technologies Market, 2014 - 2025
6.2.2 North America Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.2.3 North America Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.2.5.2 U.S. Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.2.6.2 Canada Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.3 Europe
6.3.1 Europe Epigenetics Drugs and Diagnostic Technologies Market, 2014 - 2025
6.3.2 Europe Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.3.3 Europe Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.3.5.2 Germany Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.3.6.2 UK Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Epigenetics Drugs and Diagnostic Technologies Market, 2014 - 2025
6.4.2 Asia Pacific Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.4.3 Asia Pacific Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.4.5.2 Australia Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 -
2025
6.4.6.2 New Zealand Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 -2025
6.4.7 China
6.4.7.1 China Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.4.7.2 China Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.4.8 India
6.4.8.1 India Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.4.8.2 India Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.4.9.2 Japan Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.5 South America
6.5.1 South America Epigenetics Drugs and Diagnostic Technologies Market, 2014 - 2025
6.5.2 South America Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.5.3 South America Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.5.5.2 Brazil Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.5.6.2 Mexico Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025
6.6 MEA
6.6.1 MEA Epigenetics Drugs and Diagnostic Technologies Market, 2014 - 2025
6.6.2 MEA Epigenetics Drugs and Diagnostic Technologies Market, By Type, 2014 - 2025
6.6.3 MEA Epigenetics Drugs and Diagnostic Technologies Market, By Application, 2014 - 2025

7 COMPETITIVE LANDSCAPE
7.1 Roche Diagnostics
7.1.2 Financial performance
7.1.3 Type benchmarking
7.1.4 Strategic initiatives
7.2 Thermo Fisher Scientific, Inc
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Type benchmarking
7.2.4 Strategic initiatives
7.3 Eisai Co. Ltd
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Type benchmarking
7.3.4 Strategic initiatives
7.4 Novartis AG
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Type benchmarking
7.4.4 Strategic initiatives
7.5 Illumina, Inc
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Type benchmarking
7.5.4 Strategic initiatives
7.6 Merck Sharp & Dohme Corp
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Type benchmarking
7.6.4 Strategic initiatives
7.7 Qiagen
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Type benchmarking
7.7.4 Strategic initiatives


End of the report
Disclaimer.

Content are not available

Choose License Type